Lipid Prodrug COX-2 Therapy for Mesenteric Lymphatic Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and type 2 diabetes, such as lifestyle modifications, surgery, and existing drugs, fail to effectively control the epidemic of obesity and metabolic diseases, particularly regarding the potential role of lymphatic defects, and to design novel and more effective treatments for these pathologies.
Innovation Solution
A method of treating metabolic diseases by reducing obesity-associated mesenteric lymphatic dysfunction through administering a lipid prodrug of Formula I or its pharmaceutically acceptable salt, specifically targeting the COX-2 and VEGFc/d-VEGFR3 pathways to reverse lymphatic dysfunction, inflammation, and insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drug treatments (metformin, thiazolidinediones, incretin mimetics, DPP-4 inhibitors) are used to treat metabolic diseases, then blood glucose levels can be controlled to some extent, but undesired side effects occur and adequate control is not always achieved
Solution Approach 1:
The patent uses a lipid prodrug as an intermediary carrier to deliver COX-2 inhibitor to the lymphatic system. The lipid prodrug formulation enables targeted delivery through the lymphatic route, allowing the active ingredient to reach its site of action (lymphatic vessels) while minimizing systemic exposure and associated side effects
Solution Approach 2:
The invention targets the lymphatic system specifically rather than treating the entire body systemically. By delivering the COX-2 inhibitor through the lymphatic route, the treatment achieves localized action at the site of lymphatic dysfunction, reducing off-target effects while maintaining therapeutic efficacy
2Reliability
If bariatric surgery is performed to treat obesity, then significant weight loss and metabolic improvement can be achieved, but the procedure is resource-intensive and limited to healthy patients
Solution Approach 1:
The patent replaces the mechanical/surgical intervention (bariatric surgery) with a pharmacological approach. Instead of physically altering the gastrointestinal tract through surgery, the invention uses a lipid prodrug formulation that delivers COX-2 inhibitor through the lymphatic system, achieving metabolic improvement through biochemical mechanisms rather than mechanical intervention
Solution Approach 2:
The lipid prodrug serves as an intermediary that enables oral administration of the COX-2 inhibitor to reach the lymphatic system. This intermediary approach provides a less invasive alternative to surgery, making treatment accessible to patients who would not qualify for surgical intervention
3Reliability
If lifestyle modifications (diet and physical exercise) are implemented to treat obesity, then weight control can be improved, but long-term patient compliance is difficult to maintain
Solution Approach 1:
The lipid prodrug formulation leverages the body's own lymphatic transport system to deliver the therapeutic agent. After oral administration, the formulation naturally exploits physiological lymphatic flow to reach target tissues, reducing the need for complex dosing regimens and improving long-term compliance
4Reliability
If non-lymph-targeted COX-2 inhibitors (like celecoxib) are administered to treat metabolic diseases, then some therapeutic effect can be achieved, but superior benefits are not obtained compared to lymph-targeted delivery
Solution Approach 1:
The lipid prodrug formulation creates localized concentration of the COX-2 inhibitor in the lymphatic system. By targeting the lymphatic route specifically, the invention achieves higher local drug concentration at the site of lymphatic dysfunction while reducing systemic exposure, thereby improving therapeutic efficacy and reducing side effects
Data Source
AI summary
The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.